Genome-wide screening for the G-protein-coupled receptor (GPCR) pathway-related therapeutic gene RGS19 (regulator of G protein signaling 19) in bladder cancer

Bioengineered

Xiongbing Lu¹  Guang Chen¹  Jin Kuang¹  Bing Ding¹  Weiming Lou²  Yue Liu³  Cong Wang⁴  Sainan Duan⁴  Ying Deng⁵  Yize Zhang⁶ 

[1] Department of Urology, The Second Affiliated Hospital of Nanchang University, Nanchang, Chin;Institute of Translational Medicine, Nanchang University, Nanchang, Chin;Queen Mary School, Medical Collage of Nanchang University, Nanchang, Chin;The First Affiliated Hospital of Nanchang University, Nanchang University, Jiangxi Province, Chin;The Second Affiliated Hospital of Nanchang University, Nanchang University, Jiangxi Province, Chin;The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, Jiangxi Province, Chin;

关键词: Bladder cancer;    g-protein-coupled receptor;    rgs19;    gsk1070916;    cell cycle;   

DOI  :  10.1080/21655979.2021.1971035

来源: Taylor & Francis

【 摘 要 】

Bladder cancer is one of the most severe genitourinary cancers, causing high morbidity worldwide. However, the underlying molecular mechanism is not clear, and it is urgent to find target genes for treatment. G-protein-coupled receptors are currently a target of high interest for drug design. Thus, we aimed to identify a target gene-related to G-protein-coupled receptors for therapy. We used The Cancer Genome Atlas (TCGA) and DepMap databases to obtain the expression and clinical data of RGS19. The results showed that RGS19 was overexpressed in a wide range of tumor, especially bladder cancer. We also explored its effect on various types of cancer. High expression of RGS19 was also shown to be significantly associated with poor prognosis. Cell models were constructed for cell cycle detection. shRGS19 can halt the cell cycle at a polyploid point. RGS19 is a G-protein-coupled receptor signaling pathway-related gene with a significant effect on survival. We chose RGS19 as a therapeutic target gene in bladder cancer. The drug GSK1070916 was found to inhibit the effect of RGS19 via cell rescue experiments in vitro.

【 授权许可】

CC BY